Lung carcinoma in African Americans
- 1 February 2007
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 4 (2) , 118-129
- https://doi.org/10.1038/ncponc0718
Abstract
Lung carcinoma is the most commonly diagnosed cancer and the leading cause of cancer deaths in the US. It accounts for 12% of all cancers diagnosed worldwide, making it the most common malignancy, other than nonmelanoma skin cancer. A new focus has emerged involving the role of race and ethnicity in lung carcinoma. Current health statistics data demonstrate striking disparities, which are most evident between African American patients and their white counterparts. This disparity is greatest among male patients, where statistically significant differences are seen not only in lung cancer incidence and risk, but also in survival and treatment outcomes. Several hypotheses that attempt to explain this disparity include genetic, cultural and socioeconomic differences, in addition to differences in tobacco use and exposure. Current evidence does not clearly identify the reasons for this observed disparity, or the role the aforementioned factors play in the development and overall outcomes of people with lung cancer in these populations. This disease continues to pose a considerable public health burden and more research is needed to improve understanding of the disparity of lung carcinoma statistics among African Americans. This review summarizes the existing body of knowledge regarding lung carcinoma in African Americans and attempts to identify promising areas for future investigation and intervention.Keywords
This publication has 68 references indexed in Scilit:
- Similar Outcomes Between African American and Non–African American Patients With Extensive-Stage Small-Cell Lung Carcinoma: Report From the Cancer and Leukemia Group BJournal of Clinical Oncology, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Cost-effectiveness and lung cancer clinical trialsCancer, 2003
- Tobacco use and cancer: an epidemiologic perspective for geneticistsOncogene, 2002
- Physician Perspectives on Increasing Minorities in Cancer Clinical TrialsAnnals of Epidemiology, 2000
- Glutathione S-transferase M1 polymorphism and lung cancer risk in African-AmericansCarcinogenesis: Integrative Cancer Research, 2000
- Racial Differences in the Treatment of Early-Stage Lung CancerNew England Journal of Medicine, 1999
- Genetic polymorphism of CYP2D6 and lung cancer risk in African- Americans and Caucasians in Los Angeles CountyCarcinogenesis: Integrative Cancer Research, 1997
- Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, CaliforniaPharmacogenetics, 1996